JNJ : Summary for Johnson & Johnson Common Stock - Yahoo Finance

U.S. Markets closed

Johnson & Johnson (JNJ)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
111.96+0.58 (+0.52%)
At close: 4:00 PM EST
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close111.38
Bid111.75 x 100
Ask112.04 x 100
Day's Range111.44 - 112.53
52 Week Range94.28 - 126.07
Avg. Volume7,074,422
Market Cap304.59B
PE Ratio (TTM)19.65
Earnings DateN/A
Dividend & Yield3.20 (2.86%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters12 hours ago

    Novartis CEO plays down prospects for Actelion bid - Blick

    Novartis Chief Executive Joe Jimenez has played down suggestions the Swiss drugmaker could bid for Swiss biotech group Actelion, which is in talks with U.S. healthcare group Johnson & Johnson about a transaction. Asked by Swiss Sunday newspaper SonntagsBlick whether Novartis could emerge as a white knight, he said: "We have always said that we will concentrate on complementary acquisitions in the range of $2 billion to $5 billion." He did not elaborate. Actelion is worth nearly $20 billion at Friday's closing price.

  • Reuters17 hours ago

    Actelion's silence has hedge funds betting big on J&J deal

    Actelion's silence speaks volumes to the dozens of event-driven hedge funds piling into the Swiss biotech firm, betting that Johnson & Johnson's (J&J) approach will result in an outright takeover and handsome returns. A source familiar with the matter has told Reuters the two companies are discussing a bid of close to $27 billion, or 250 Swiss francs ($248) per share, which is 25 percent above Actelion's current share price. Both companies have confirmed that U.S. diversified healthcare group J&J - maker of Pizbuin sun screen, surgical tools and arthritis drug Remicade - has approached Actelion about a potential takeover, but kept mum on details.

  • Forget Pfizer: Here Are 3 Better Dividend Stocks
    Motley Fool2 days ago

    Forget Pfizer: Here Are 3 Better Dividend Stocks

    Love dividends? Check out these three.